Dextranomer and Hyaluronate Derivatives (Solesta) and Ibritumomab Intravenous
Determining the interaction of Dextranomer and Hyaluronate Derivatives (Solesta) and Ibritumomab Intravenous and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: dextranomer / sodium hyaluronate
Brand name: Solesta
Synonyms: Dextranomer and sodium hyaluronate
Generic Name: ibritumomab
Brand name: Y-90 Zevalin, In-111 Zevalin
Synonyms: Ibritumomab, Ibritumomab Tiuxetan
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Dextranomer and Hyaluronate Derivatives (Solesta)-Ibritumomab Tiuxetan
- Dextranomer and Hyaluronate Derivatives (Solesta)-Ibrutinib
- Dextranomer and Hyaluronate Derivatives (Solesta)-Ibrutinib Capsules
- Dextranomer and Hyaluronate Derivatives (Solesta)-Ibrutinib Tablets
- Dextranomer and Hyaluronate Derivatives (Solesta)-Ibu
- Dextranomer and Hyaluronate Derivatives (Solesta)-IBU Tablets
- Ibritumomab Intravenous-Dextranomer and sodium hyaluronate
- Ibritumomab Intravenous-Dextroamphetamine
- Ibritumomab Intravenous-Dextroamphetamine and amphetamine
- Ibritumomab Intravenous-Dextroamphetamine and Amphetamine Extended-Release Capsules (Adderall XR)
- Ibritumomab Intravenous-Dextroamphetamine and Amphetamine Extended-Release Capsules (Mydayis)
- Ibritumomab Intravenous-Dextroamphetamine and Amphetamine Tablets